In recent years, fungal mycelium has rapidly emerged as a promising novel food ingredient in the alternative protein sector. Mycelium, a network of filamentous cells (hyphae) produced by fungi, can be cultivated via fermentation to generate protein-rich biomass (commonly referred to as "mycoprotein"), which is increasingly utilized in meat analogues and fermented food products.
REACH24H provides an in-depth analysis of the food applications, safety profile, and regulatory requirements for fungal mycelium under both the EU Novel Food framework and the U.S. regulatory system, helping companies better understand the key compliance considerations when planning market entry in these two markets.
Why Fungal Mycelium Is Gaining Attention
The application of fungal mycelium in food is not entirely a novel concept. Traditional Indonesian fermented food, tempeh, has utilized fungal mycelium, for instance, Rhizopus oligosporus, to ferment soybeans for centuries. In recent years, modern technologies have enabled the precise cultivation of mycelium in bioreactors, yielding a highly efficient and controllable protein source, as exemplified by the QuornTM meat analogue developed in the United Kingdom, which is based on the Fusarium venenatum strain. This production approach is not only efficient but also significantly reduces the environmental footprint.
The primary advantages of mycelium-based foods include:
High Production Efficiency: Fungi can rapidly convert carbohydrates into proteins with high yield.
Superior Texture Structure: The naturally formed fibrous structure of mycelium mimics the texture of meat.
Sustainability: Compared to conventional animal husbandry, mycelium production requires substantially less land, water, and generates fewer greenhouse gas emissions.
EU Novel Food and U.S. GRAS Regulatory Frameworks
Despite the significant potential of fungal mycelium-based foods, their market entry is largely contingent upon regulatory approvals. The following outlines the primary regulatory frameworks in the EU and the U.S.:
1. The EU: Novel Food Regulation
Under Regulation (EU) 2015/2283 on Novel Foods, most mycelium-derived ingredients are classified as novel foods, unless it can be demonstrated that they were widely consumed within the EU prior to 1997. Applicants are required to submit a comprehensive technical dossier, including:
Taxonomic identification of the fungal species and strain;
Manufacturing process description (including contamination control measures);
Compositional data and product specifications;
Toxicological assessment (e.g., genotoxicity and 90-day feeding studies);
Allergenicity evaluation;
Consumer exposure assessment.
The European Food Safety Authority (EFSA) is responsible for the risk assessment, following which the European Commission decides on the final authorization. A notable milestone in the sector was achieved in 2025, when the Dutch company The Protein Brewery received a positive EFSA opinion for its mycoprotein Fermotein®, derived from Rhizomucor pusillus.
For further regulatory context, review the European Commission Novel Food Authorisations page, the EFSA Scientific Opinion on Rhizomucor pusillus, and Commission Implementing Regulation (EU) 2026/1507.
2. The U.S.: GRAS Determination
In the United States, mycelium-based foods can enter the market through the Generally Recognized as Safe (GRAS) pathway. Companies may either submit a GRAS notification to the FDA or self-affirm GRAS status through an independent panel of qualified experts.
Similar to the EU framework, the U.S. assessment also requires data on strain identity, manufacturing processes, toxicology, and allergenicity; however, the review process is generally faster. Several mycelium-derived proteins have already obtained GRAS status. For instance, FyTM Protein, developed by the U.S.-based company Nature’s Fynd from Fusarium flavolapis, received an FDA “no question” letter in 2021 and has since been successfully commercialized in a range of products.
For the supporting FDA records, review GRAS Notice No. 904 and FDA's agency response letter.
Safety Considerations for Mycelium-Based Foods
Despite the considerable promise of mycelium-based foods, their safety must be rigorously evaluated. The following are key safety considerations:
Non-pathogenic Strains: Only fungal strains that are known to be non-toxic and non-pathogenic should be utilized. For instance, the Fusarium venenatum A3/5 strain used in QuornTM has undergone extensive testing to confirm that it does not produce harmful mycotoxins under fermentation conditions.
Allergenicity and Digestibility: The mycelial cell wall contains chitin, a type of dietary fiber, which may cause mild gastrointestinal discomfort in a small subset of individuals. Furthermore, while mycelium proteins are generally considered to have low allergenic potential, individuals with known mold allergies may exhibit sensitivity, underscoring the importance of clear labeling.
Metabolic Safety: Early single-cell protein products raised concerns regarding elevated uric acid levels due to high RNA content. Modern mycelium-based products address this issue through processing steps such as heat treatment or cell inactivation, which effectively reduce RNA content (typically to below 2%).
Nutritional Value: Mycelium-based foods are rich in protein, low in fat, and cholesterol-free. However, they tend to have low levels of vitamin B12, which should be supplemented through dietary sources or fortification.
Industry Impact and Compliance Recommendations
1. Industry Impact
Production and Research: Companies must allocate resources to develop manufacturing processes that align with regulatory requirements, while ensuring strain safety and product consistency.
Market Access: The EU's lengthy approval process may delay product launches, whereas the U.S. GRAS pathway offers greater flexibility, making it a suitable option for companies seeking faster market entry.
Consumer Trust: Products that have undergone regulatory approval are more likely to gain consumer confidence, particularly in markets with high food safety awareness.
2. Compliance Recommendations
Early Planning: Integrate regulatory considerations at the initial stage of product development, ensuring that strain selection, manufacturing processes, and toxicological data meet applicable standards.
Data Preparation: Compile a comprehensive technical dossier, including strain identification, toxicological studies, and allergenicity assessments.
Labeling Management: Clearly disclose allergen information to enhance consumer transparency.
Expert Collaboration: Partner with professional organizations to optimize the regulatory application process.
How REACH24H Can Support Fungal Mycelium Market Access
For companies developing fungal mycelium, mycoprotein, or other fermentation-derived food ingredients, early regulatory assessment can help clarify the applicable market-entry pathway, identify potential data gaps, and support more efficient product development and compliance planning.
Based on the target market, fungal strain, manufacturing process, product specifications, and intended uses, REACH24H can support companies with:
EU Novel Food status and regulatory pathway assessment;
U.S. GRAS pathway assessment and regulatory strategy;
Technical data and dossier gap analysis;
Regulatory dossier preparation and submission support;
Safety and testing requirement assessment;
Labeling and compliance review; and
Regulatory monitoring and post-submission support.
For an initial assessment, companies may provide available information on the fungal species and strain, manufacturing process, product composition and specifications, intended food uses, target market, and existing safety data. This information can help determine the likely regulatory pathway and identify key compliance requirements at an early stage.
Share your product information with REACH24H for an initial regulatory assessment. Our team can help you evaluate the applicable EU Novel Food or U.S. GRAS pathway, identify potential data gaps, and clarify the next steps for market access.
Regulatory Outlook for Fungal Mycelium Foods
Fungal mycelium is steadily emerging as a cornerstone of the alternative protein sector, offering a sustainable and nutritionally rich protein source. However, its commercialization in the European Union continues to be challenged by regulatory approval requirements. With positive EFSA opinions on products such as Fermotein®, the coming years are likely to witness a growing number of mycelium-based food products entering the market.
For companies operating in this space, early engagement with compliance planning, combined with a robust commitment to product safety and transparency, will be instrumental in capturing a competitive advantage. As regulatory frameworks evolve further and consumer demand continues to rise, mycelium-based foods are expected to occupy an increasingly significant position within the global food system.
Companies should initiate compliance preparations at the earliest opportunity to secure a competitive edge in this rapidly evolving sector.
Planning to Bring a Fungal Mycelium Ingredient to the EU or U.S. Market?
Whether you are assessing the regulatory status of a fungal mycelium ingredient or preparing for an EU Novel Food or U.S. GRAS project, REACH24H can help you clarify the applicable regulatory pathway, identify potential data gaps, and plan the next steps for market access.
Related REACH24H Resources
Explore EU Novel Food status assessment, data-gap analysis, dossier preparation, EFSA submission, and post-authorisation compliance support.
Learn about U.S. GRAS pathway assessment, data-gap analysis, safety evaluation, and FDA GRAS notification support.
Review the latest FDA proposal to introduce mandatory GRAS notification and its potential implications for food ingredient companies.
Understand key GRAS requirements and compliance considerations for novel and fermentation-derived food ingredients.
Compare novel food ingredient regulatory pathways across the EU, U.S., China, and other major markets.
Explore REACH24H's broader food ingredient regulatory assessment and global market-access support.
